| Online: | |
| Visits: | |
| Stories: |
Senate Criticizes Gilead Over Hepatitis C Drug Prices
Thursday, December 3, 2015 1:39
% of readers think this story is Fact. Add your two cents.
An 18-month investigation has culminated in a bipartisan Senate report released yesterday that delivers strong criticism of drug maker Gilead over its pricing of two hepatitis cures. The report accuses Gilead of placing profits well above patient access and being highly resistant to price reductions.
The two drugs that prompted the investigation are Sovaldi and Harvoni. Sovaldi was developed by another drug manufacturer, which Gilead later purchased. It was the first drug capable of curing hepatitis C but cost $1,000 per pill, or $84,000 for the full 12 week treatment. The follow-up drug, Harvoni, cures more forms of hepatitis and had a full treatment course costing $94,500.
Read full news: http://www.doctorshealthpress.com/health-news/senate-criticizes-gilead-over-hepatitis-c-drug-prices
